Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSPE.L Regulatory News (SPE)

  • There is currently no data for SPE

Contract Win

16 Oct 2007 07:01

Sopheon PLC16 October 2007 Embargoed Release: 07:00hrs Tuesday 16 October 2007 Sopheon plc ('Sopheon') Beiersdorf Implements Sopheon System in Support of Product Innovation Strategy Accolade(R) Helps Skin Care Market Leader Integrate Management of Global Product Development Process Sopheon, the international software and services company, announced today thatBeiersdorf AG, a leading manufacturer of skin and beauty care products, hasdeployed Sopheon's Accolade product life cycle management (PLM) system tosupport the company's implementation of an enhanced, integrated process fordeveloping and launching new products. The solution is also being used tostrengthen product portfolio decision-making and reporting. Founded in Hamburg, Germany in 1882 by pharmacist Carl Beiersdorf, Beiersdorf'soriginal product patents were for bandages and wound coverings. By the turn ofthe century, the company had expanded into consumer skin care and beautyproducts. Today Beiersdorf is a $7B global producer of regionally brandedconsumer goods with approximately 100 locations and more than 17,000 employees. The company has a reputation for strong customer and product focus, anorientation that has helped, for instance, make NIVEA(R) the best-selling bodycare brand in the world. Cosmetics is a highly competitive, global industry. It is also among thefastest-moving markets in the consumer goods sector. The life of a typicalcosmetic product is only about four years, which means that ongoing, rapidinnovation is a prerequisite to achieving sustained business growth. Beiersdorfis addressing this imperative as a core aspect of its consumer businessstrategy, labeled "Passion for Success." The strategy calls for the company tofocus on fewer but more significant innovations and deliver them to marketfaster. Beiersdorf has long regarded continuous improvement of its new productdevelopment processes as a key factor in maintaining brand superiority. Beiersdorf's adoption of Accolade has allowed the company to advance not onlyits processes for product creation, but its portfolio management capabilities aswell. One principal benefit of the system is that it has given thecross-functional teams engaged in product development across the Beiersdorforganization a common platform through which to access and share project data.The result has been greater transparency and an improved ability to track theprogress of projects in the developmental pipeline. Accolade has also helped toraise the efficiency and accuracy of portfolio reporting and strengthen thecompany's portfolio management and decision-making processes. Sopheon partners Sopheon Vertriebs GmbH and Sopheon Business Applications GmbHwere responsible for the sale, implementation and support of Accolade atBeiersdorf. Dieter Jaeger, chief executive officer of Sopheon Vertriebs GmbH,said, "Beiersdorf has commanded a top position in the international personalcare market for many years, and innovation-led product development has been ahallmark of their success. When we were introduced to Beiersdorf, they alreadyhad in place a standardized, global product development process anchored in bestpractices. With Accolade, we were able to give them a single, user-friendlysoftware system that integrated the management of that process with portfoliomanagement and comprehensive decision-support. Beiersdorf chose Accoladebecause it could match their specific, demanding process requirements. Theyhave subsequently embraced it because it has proven that it helps to ensuresuperior process performance." Accolade(R) is a registered trademark of Sopheon plc. NIVEA(R) is a registered trademark of Beiersdorf AG. All other trademarks and registered trademarks are the sole property of their respective owners. About Beiersdorf AG Founded in Hamburg, Germany in 1882 as a small pharmacy, Beiersdorf has grown tobecome a global company of branded consumer goods with approximately 100affiliates. Since its founding, Beiersdorf has concentrated on skin and beautycare. Beiersdorf is focused on dynamic regions that have above-averagedevelopmental potential, including Asia, South America and Eastern Europe.Beiersdorf is particularly focused on China, Russia, Brazil and India.Beiersdorf products include NIVEA(R), Eucerin(R), Curad(R), Labello(R), 8x4(R),JUVENA(R), la prairie(R), atrix(R) and FUTURO(R). For more information, pleasevisit www.beiersdorf.com. About Sopheon Sopheon (LSE:SPE) is an international provider of software and services thathelp organizations improve the business impact of product innovation. Sopheon'ssolutions automate and govern the innovation process, enabling companies toincrease revenue and profits from new products. Sopheon is listed on the AIMMarket of the London Stock Exchange and on the Euronext in the Netherlands. Formore information, please visit www.sopheon.com. - Ends - For further information contact: Barry Mence, Chairman Sopheon plc Tel : + 44 (0) 1483 685 735Arif Karimjee, CFOAndrew Tan Hansard Tel : + 44 (0) 207 245 1100 + 44 (0) 7957 203 685Floor van Maaren Citigate First Financial Tel : + 31 (0) 205 754 010 This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
30th Jan 201810:27 amRNSIssue of Equity
29th Jan 20187:00 amRNSTrading Update
4th Jan 20182:05 pmRNSSecond Price Monitoring Extn
4th Jan 20182:00 pmRNSPrice Monitoring Extension
4th Jan 20187:00 amRNSTrading Update
22nd Dec 20171:01 pmRNSHolding(s) in Company
22nd Dec 201712:37 pmRNSConversion of Loan Stock
8th Dec 20177:00 amRNSAmendment to the Terms of Convertible Loan Stock
9th Nov 20177:00 amRNSCertis Europe Partners with Sopheon
19th Oct 20177:00 amRNSSopheon Funding Award
11th Oct 201710:44 amRNSDirector/PDMR Shareholding
2nd Oct 20177:00 amRNSIssue of Equity
26th Sep 20177:00 amRNSSopheon "Leader" in Strategic Portfolio Management
5th Sep 20177:00 amRNSSopheon's Accolade Software beyond innovation
24th Aug 20177:00 amRNSHalf Yearly Report
21st Jul 201710:32 amRNSDirector Shareholdings
6th Jul 20177:00 amRNSAccolade Release 11.2
29th Jun 20177:00 amRNSNew Approach to Product Development with Accolade
13th Jun 201712:04 pmRNSDirector Shareholdings
8th Jun 201712:09 pmRNSResult of AGM
8th Jun 20177:00 amRNSAGM Statement
26th May 20174:33 pmRNSIssue of Equity
26th Apr 20173:50 pmRNSIssue of Equity
12th Apr 201712:01 pmRNSIssue of Equity
7th Apr 20171:37 pmRNSDirector Shareholdings
31st Mar 20177:00 amRNSDirector Shareholdings
31st Mar 20177:00 amRNSIssue of Equity
23rd Mar 20177:00 amRNSFinal Results
23rd Feb 20177:00 amRNSAccolade Release 11.1
16th Feb 20177:00 amRNSGrant of Options / PDMR dealing
30th Jan 20177:00 amRNSTrading Update
21st Nov 201611:50 amRNSIssue of Equity
3rd Nov 20168:00 amRNSAccolade Release 11.0
29th Sep 201612:41 pmRNSIssue of Equity
22nd Sep 20169:09 amRNSIssue of Equity
15th Sep 20163:09 pmRNSIssue of Equity
25th Aug 20167:00 amRNSHalf Yearly Report
28th Jul 20165:01 pmRNSHolding(s) in Company
26th Jul 201610:49 amRNSHolding(s) in Company
12th Jul 201610:48 amRNSHolding(s) in Company
29th Jun 20165:32 pmRNSDirector Dealing
16th Jun 20164:22 pmRNSDirector Dealing
14th Jun 20164:18 pmRNSDirector Dealing
10th Jun 20162:13 pmRNSDirector Dealing
9th Jun 201611:37 amRNSResult of AGM
9th Jun 20167:00 amRNSAGM Statement
31st May 20163:09 pmRNSIssue of Equity
5th May 20161:25 pmRNSHolding(s) in Company
4th May 20167:00 amRNSAccolade Release 10.3
3rd May 20161:27 pmRNSDirector Shareholdings

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.